Characteristics | All patients (n = 24) |
---|---|
Age, years | 69 [61–73] |
Sex | |
 Female | 6 (25%) |
 Male | 18 (75%) |
Body mass index, kg/m2 | 27.5 [24.3–31.1] |
Any comorbidities | 19 (79%) |
 Diabetes | 7 (29%) |
 Hypertension | 6 (25%) |
 Cardiovascular disease | 7 (29%) |
 Chronic obstructive pulmonary disease | 3 (13%) |
 Malignancy | 10 (42%) |
 Chronic liver disease | 0 (0%) |
 Chronic kidney disease | 1 (4%) |
 Immunocompromised* | 5 (17%) |
APACHE II | 17 [11–21] |
Time from illness onset to ICU admission, days | 11 [8–13] |
Medication use | |
 Norepinephrine use | 20 (83%) |
  Maximum infusion rate in first 24 h on ICU, μg/kg/min | 0.11 [0.07–0.21] |
 Corticosteroids | 1 (4%) |
 Remdesivir | 3 (13%) |
 Chloroquine | 19 (79%) |
 Anakinra | 1 (4%) |
Symptoms and (laboratory) parameters | |
 Heart rate, bpm | 83 [71–112] |
 Mean arterial pressure, mmHg | 77 [72–81] |
 Fluid balance in first 24 h on ICU, mL | 1348 [680–1881] |
 Urine output in first 24 h on ICU, mL | 1105 [888–1486] |
 Creatinine, μmol/L | 86 [70–133] |
 Dialysis | 0 (0%) |
 Mechanical ventilation (invasive) | 24 (100%) |
  Tidal volume, mL/kg | 5.3 [4.4–6.0] |
  Respiratory rate, bpm | 21 [20–24] |
  PEEP, cm H2O | 12 [10–14] |
  FiO2, % | 50 [41–60] |
 P/F ratio | 164 [136–189] |
  100–200 | 20 (83%) |
  200–300 | 4 (17%) |
 Thrombocytes, 109/L | 239 [151–274] |
 Leukocytes, 109/L | 8.2 [5.3–11.6] |
 C-reactive protein, mg/L | 301 [157–316] |
 Procalcitonin, μg/L | 0.72 [0.29–3.66] |
 Ferritin, μg/L | 1216 [488–1834] |
 Lactate (highest over last 24 h), mmol/L | 1.2 [1.1–1.7] |
 D-dimer, ng/mL | 3075 [1780–4598] |
 Troponin I, ng/L | 23 [13–44] |
 Albumin, g/L | 20 [17–22] |
 Alanine aminotransferase, U/L | 34 [21–41] |
 Aspartate aminotransferase, U/L | 48 [31–73] |
 Creatinine kinase, U/L | 136 [56–357] |
 Lactate dehydrogenase, U/L | 398 [303–499] |
Outcome parameters | |
 Secondary infections | 0 (0%) |
 Death | 2 (8%) |